CPIX Stock Forecast 2025-2026
Distance to CPIX Price Targets
CPIX Price Momentum
10 Quality Stocks Worth Considering Now
Researching Cumberland Pharma (CPIX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CPIX and similar high-potential opportunities.
Latest CPIX Stock Price Targets & Analyst Predictions
CPIX has shown a year-to-date change of 100.8% and a 1-year change of 197.5%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for CPIX. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CPIX Analyst Ratings
CPIX Price Target Range
Latest CPIX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CPIX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 3, 2019 | B. Riley | Buy | Maintains | $0.00 | |
| Dec 3, 2019 | B. Riley Securities | Andrew D'Silva | Buy | Maintains | $9.75 |
| Nov 18, 2019 | B. Riley FBR | Buy | Maintains | $0.00 | |
| Nov 18, 2019 | B. Riley Securities | Buy | Maintains | $9.00 | |
| Aug 17, 2018 | B. Riley Securities | Andrew D'Silva | Buy | Maintains | $8.75 |
| Aug 17, 2018 | B. Riley FBR | Buy | Maintains | $0.00 | |
| May 5, 2018 | B. Riley FBR | Buy | Initiates | $0.00 | |
| Apr 17, 2018 | B. Riley Securities | Buy | Initiates | $0.00 | |
| Apr 17, 2018 | B. Riley FBR | Buy | Initiates | $0.00 | |
| Apr 10, 2013 | UBS | Neutral | Maintains | $5.50 | |
| Nov 12, 2012 | UBS | Neutral | Maintains | $5.00 | |
| Nov 9, 2012 | Wells Fargo | Market Perform | Downgrade | $0.00 |
Cumberland Pharmaceuticals Inc. (CPIX) Competitors
The following stocks are similar to Cumberland Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cumberland Pharmaceuticals Inc. (CPIX) Financial Data
Cumberland Pharmaceuticals Inc. has a market capitalization of $66.49M with a P/E ratio of -10.3x. The company generates $37.87M in trailing twelve-month revenue with a -17.1% profit margin.
Revenue growth is +11.6% quarter-over-quarter, while maintaining an operating margin of -17.7% and return on equity of -24.9%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Cumberland Pharmaceuticals Inc. (CPIX) Business Model
About Cumberland Pharmaceuticals Inc.
Develops and commercializes specialty prescription products.
Cumberland Pharmaceuticals operates by developing niche-market prescription products that target specific medical needs, generating revenue through direct sales and partnerships with healthcare providers and distributors. The company focuses on acute care, gastroenterology, and oncology segments, ensuring broad availability of its innovative treatments in the U.S. market.
Founded in 1999 and headquartered in Nashville, Tennessee, Cumberland is dedicated to improving patient care and addressing unmet medical needs, which positions it as a significant player in the healthcare sector.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
91
CEO
Mr. A. J. Kazimi MBA
Country
United States
IPO Year
2009
Website
www.cumberlandpharma.comCumberland Pharmaceuticals Inc. (CPIX) Latest News & Analysis
FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference
30 days agoCumberland Pharmaceuticals (Nasdaq: CPIX) reported a 5.4% improvement in cardiac function from its Phase 2 FIGHT DMD trial, with results presented at the MDA Conference.
Ifetroban's significant improvement in cardiac function could indicate strong potential for future sales, influencing Cumberland Pharmaceuticals' stock performance and investor sentiment.
Cumberland Pharmaceuticals Inc. will host its Q4 2024 Earnings Conference Call on March 4, 2025, at 4:30 PM ET, featuring key company executives.
Cumberland Pharmaceuticals' earnings call provides insights into financial performance and future strategies, critical for evaluating the company's investment potential and market position.
Cumberland Pharmaceuticals (NASDAQ: CPIX) reported Q4 2024 net revenues of $10.4 million, up 11.6% year-over-year, alongside expanded product labeling and FDA designations.
Cumberland Pharmaceuticals’ revenue growth signals strong market performance and potential for future profitability, which can positively affect stock value and investor confidence.
Cumberland Pharmaceuticals Inc. (CPIX) will release its 2024 financial results and company update on March 4, 2025, after market close.
Cumberland Pharmaceuticals' upcoming financial results and company update could significantly influence stock performance and investor sentiment, impacting market positions and valuations.
VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA
2 months agoCumberland Pharmaceuticals and SciClone announced NMPA approval for Vibativ® in China, enabling its launch in the second-largest pharmaceutical market.
Approval of Vibativ® in China opens a significant market opportunity for Cumberland Pharmaceuticals, potentially boosting revenue and market share in a large pharmaceutical market.
Cumberland Pharmaceuticals Inc. (CPIX) announced topline results from its Phase 2 FIGHT DMD trial on Tuesday.
Cumberland Pharmaceuticals' Phase 2 trial results can impact stock performance and investor sentiment, influencing future funding, partnerships, and market potential for its treatments.
Frequently Asked Questions About CPIX Stock
What is Cumberland Pharmaceuticals Inc.'s (CPIX) stock forecast for 2025?
Analyst forecasts for Cumberland Pharmaceuticals Inc. (CPIX) are not currently available. The stock is trading at $4.76.
Is CPIX stock a good investment in 2025?
According to current analyst ratings, CPIX has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.76. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CPIX stock?
Price predictions from Wall Street analysts for CPIX are not currently available. The stock is trading at $4.76.
What is Cumberland Pharmaceuticals Inc.'s business model?
Cumberland Pharmaceuticals operates by developing niche-market prescription products that target specific medical needs, generating revenue through direct sales and partnerships with healthcare providers and distributors. The company focuses on acute care, gastroenterology, and oncology segments, ensuring broad availability of its innovative treatments in the U.S. market.
What is the highest forecasted price for CPIX Cumberland Pharmaceuticals Inc.?
Price targets from Wall Street analysts for CPIX are not currently available. The stock is trading at $4.76.
What is the lowest forecasted price for CPIX Cumberland Pharmaceuticals Inc.?
Price targets from Wall Street analysts for CPIX are not currently available. The stock is trading at $4.76.
What is the overall CPIX consensus from analysts for Cumberland Pharmaceuticals Inc.?
The overall analyst consensus for CPIX is neutral. Out of 2 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are CPIX stock price projections?
Stock price projections, including those for Cumberland Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.